Though Meehan was cautious on Waters in the near term, he provided a favorable outlook on Thermo Fisher Scientific.
The Swiss company markets the WAVE system, a waveguide interferometry-based instrument for studying molecular interactions in real time.
More powerful and user-friendly mass spec systems could drive an uptick in interest in the technique, suggested a leading top-down researcher.
The company's Q2 revenues were up less than 1 percent from $596.2 million in Q2 2018, and short of the average Wall Street estimate of $601.4 million.
The new partnership will support the analysis of glycans in 30,000 human samples by the end of 2021.
New instrument releases at this week's meeting reflected proteomics' increased emphasis on throughput and the continuing spread of ion mobility technology.
The index, which underperformed the Dow Jones and the Nasdaq, fell nearly 3 percent in April.
The company posted revenues of $513.9 million for the quarter compared to $530.7 million in Q1 2018, below the average Wall Street estimate of $545.3 million.
Developed in collaboration with Waters and Labcyte, the platform enables applications including high-throughput drug screening and metabolomic profiling.
Driven by strong pharma sales, revenues increased to $715 million from $687 million in Q4 2017, besting the consensus analyst estimate of $703 million.
In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.
Canadian regulators are beginning to share information from new drug studies, Undark reports.
Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.
In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.